Patents by Inventor Michal Neeman
Michal Neeman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9492100Abstract: The invention provides magnetic resonance imaging methods for detecting cardiac diseases including myocardial fibrosis. Specifically, the invention provides a magnetic resonance imaging (MRI) pulse sequence that could be used to perform magnetization transfer (MT) or chemical exchange saturation transfer (CEST) in the heart.Type: GrantFiled: April 2, 2014Date of Patent: November 15, 2016Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michal Neeman, Moriel Vandsburger
-
Patent number: 9387264Abstract: The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.Type: GrantFiled: April 4, 2013Date of Patent: July 12, 2016Assignees: YEDA RESEARCH AND DEVELOPMENT CO. LTD., THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEVInventors: Michal Neeman, Raz Zarivach, Marina Radoul, Batya Cohen, Moriel Vandsburger, Limor Lewin
-
Publication number: 20140303479Abstract: The invention provides magnetic resonance imaging methods for detecting cardiac diseases including myocardial fibrosis. Specifically, the invention provides a magnetic resonance imaging (MRI) pulse sequence that could be used to perform magnetization transfer (MT) or chemical exchange saturation transfer (CEST) in the heart.Type: ApplicationFiled: April 2, 2014Publication date: October 9, 2014Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.Inventors: Michal Neeman, Moriel Vandsburger
-
Publication number: 20130280173Abstract: The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.Type: ApplicationFiled: April 4, 2013Publication date: October 24, 2013Inventors: Michal NEEMAN, Raz Zarivach, Marina Radoul, Batya Cohen, Moriel Vandsburger, Limor Lewin
-
Publication number: 20100291036Abstract: The present invention relates to compounds and methods for inhibiting the expression of vascular endothelial growth factor-C (VEGF-C) in a target cell. Particularly, the present invention relates to antisense polynucleotides complementary to a lens epithelium-derived growth factor (LEDGF/p75) mRNA and uses thereof for inhibiting tumor progression and tumor metastasis. The present invention further relates to uses of LEDGF/p75 polypeptide or a nucleic acid encoding same for treating endothelial cell related conditions, particularly inflammation and edema.Type: ApplicationFiled: January 25, 2009Publication date: November 18, 2010Applicant: YEDA RESEARCH AND DEVELOPMENT CO.LTD, at The Weizmann Institute of ScienceInventors: Michal Neeman, Batya Cohen, Stav Sapoznik, Shifra Ben-Dor, Gila Meir
-
Patent number: 7715901Abstract: An online Blood Oxygenation Level-Dependent (BOLD)-magnetic resonance imaging (MRI) method for functional clinical guidance or monitoring a therapeutic modality involving treatment by a sensitizer which, upon excitation by the appropriate sensitizing radiation, initiates local oxygen consumption, comprising: (i) generating a BOLD-weighted MR-image of the target region of interest within the patient's body (time t0); (ii) administering said sensitizer to the patient; (iii) irradiating the target region while the patient is subjected to continuous MR imaging; (iv) generating a sole or a plurality of T2* weighted sequential BOLD MR-images during and/or after irradiation (time t); (v) processing the data generated at time t0 and time t and generating a color-coded difference or ratio map on a pixel by pixel basis; and (vi) analyzing the processed data. The method is preferably applied to photodynamic therapy (PDT).Type: GrantFiled: May 8, 2003Date of Patent: May 11, 2010Assignee: Yeda Research and Development Co. Ltd.Inventors: Yoram Salomon, Michal Neeman, Avigdor Scherz, Shimon Gross, Assaf Gilead
-
Patent number: 7485181Abstract: A composition-of-matter is provided. The composition-of-matter comprising a chelator moiety-hyaluronan complex bound to a solid support. Also provided are methods of in-situ assessing hyaluronidase activity using such compositions.Type: GrantFiled: October 7, 2004Date of Patent: February 3, 2009Assignee: Yeda Research and Development Co. Ltd.Inventors: Michal Neeman, Liora Shiftan
-
Patent number: 7208138Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.Type: GrantFiled: December 5, 2005Date of Patent: April 24, 2007Assignees: Duke University, Yeda Research and Development Co., Ltd.Inventors: Zishan Haroon, Mark W. Dewhirst, Charles S. Greenberg, Michal Neeman
-
Publication number: 20060135868Abstract: An online Blood Oxygenation Level-Dependent (BOLD)-magnetic resonance imaging (MRI) method for functional clinical guidance or monitoring a therapeutic modality involving treatment by a sensitizer which, upon excitation by the appropriate sensitizing radiation, initiates local oxygen consumption, comprising: (i) generating a BOLD-weighted MR-image of the target region of interest within the patient's body (time t0); (ii) administering said sensitizer to the patient; (iii) irradiating the target region while the patient is subjected to continuous MR imaging; (iv) generating a sole or a plurality of T2* weighted sequential BOLD MR-images during and/or after irradiation (time t); (v) processing the data generated at time t0 and time t and generating a color-coded difference or ratio map on a pixel by pixel basis; and (vi) analyzing the processed data. The method is preferably applied to photodynamic therapy (PDT).Type: ApplicationFiled: January 20, 2006Publication date: June 22, 2006Applicant: Yeda Research and Development Co., Ltd.Inventors: Yoram Salomon, Michal Neeman, Avigdor Scherz, Shimon Gross, Assaf Gilad
-
Publication number: 20060083689Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.Type: ApplicationFiled: December 5, 2005Publication date: April 20, 2006Applicants: Duke University, Yeda Research and Development Co., Ltd.Inventors: Zishan Haroon, Mark Dewhirst, Charles Greenberg, Michal Neeman
-
Publication number: 20060078500Abstract: A composition-of-matter is provided. The composition-of-matter comprising a chelator moiety-hyaluronan complex bound to a solid support. Also provided are methods of in-situ assessing hyaluronidase activity using such compositions.Type: ApplicationFiled: October 7, 2004Publication date: April 13, 2006Inventors: Michal Neeman, Liora Shiftan
-
Patent number: 6972122Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.Type: GrantFiled: December 18, 2001Date of Patent: December 6, 2005Assignees: Duke University, Yeda Research and Development Co., Ltd.Inventors: Zishan Haroon, Mark W. Dewhirst, Charles S. Greenberg, Michal Neeman
-
Patent number: 6694171Abstract: A delivery system and method for targeting a contrast agent to tissues and organs for improved diagnosis of tumors and for prognosis and follow-up of cancer therapy by X-ray imaging. The delivery system includes a conjugate or complex of a macromolecular carrier and a contrast agent selected from the group consisting of: (a) a compound having a heavy element with an atomic number in the range of 75 to 92, and (b) a compound having an element with a property of an abrupt change in its X-ray attenuation coefficient within the energy range used for radiography, said macromolecular carrier of said conjugate or complex being optionally linked to a specific tissue marker molecule.Type: GrantFiled: March 6, 2000Date of Patent: February 17, 2004Assignee: Yeda Research and DevelopmentInventors: Amos Breskin, Rachel Chechik, Zvi Paltiel, Bilha Schechter, Abraham Warshawsky, Abraham Shanzer, Michal Neeman
-
Patent number: 6670337Abstract: The method of the present invention provides a means for protecting a patient, including a transplant patient, from reperfusion injury by administering CM101 or GBS toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. The present invention also includes a method to protect a tissue or organ against reperfusion injury in a transplant patient.Type: GrantFiled: July 29, 1999Date of Patent: December 30, 2003Assignees: Yeda Reaearch and Development Co., Ltd., Vanderbilt UniversityInventors: Carl G. Hellerqvist, Michal Neeman, Barbara D. Wamil, Rinat Abramovitch
-
Publication number: 20030212041Abstract: The method of the present invention provides a means of treating a patient having a wound, especially by minimizing scarring and accelerating wound healing, by administering CM101 or GBS toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria. Types of wounds that may be treated include surface and internal wounds. The method of the present invention also includes administration of CM101 or GBS toxin to surgery patients having tumors in order to facilitate wound healing and minimize the likelihood of tumor progression.Type: ApplicationFiled: June 17, 2003Publication date: November 13, 2003Inventors: Carl G. Hellerqvist, Michal Neeman, Barbara D. Wamil, Rinat Abramovitch
-
Publication number: 20030180331Abstract: The method of the present invention provides a means of treating a patient having a wound, especially by minimizing scarring and accelerating wound healing, by administering CM101 or GBS toxin isolated from Group B &bgr;-hemolytic streptococcus bacteria. The method of the present invention also includes administration of CM101 or GBS toxin to surgery patients having tumors in order to facilitate wound healing and minimize the likelihood of tumor progression.Type: ApplicationFiled: March 24, 2003Publication date: September 25, 2003Inventors: Carl G. Hellerqvist, Michal Neeman, Barbara D. Wamil, Rinat Abramovitch
-
Patent number: 6569838Abstract: The present invention includes a means of treating a patient having a keloid. Specifically, the invention includes a method for excising the keloid and administering a GBS toxin isolated from Group B &bgr;-hemolytic Streptococcus bacteria.Type: GrantFiled: October 7, 1998Date of Patent: May 27, 2003Assignees: Vanderbilt University, Yeda Research & Development Ltd.Inventors: Carl G. Hellerqvist, Michal Neeman, Barbara D. Wamil, Rinat Abramovitch
-
Publication number: 20020136692Abstract: Imaging agents for magnetic resonance imaging are disclosed. Methods of monitoring angiogenesis and the growth and remission of tumor tissue are also disclosed. Methods of monitoring blood clot formation and dissolution are additionally disclosed. Methods of monitoring wound healing are further disclosed. A kit for obtaining an image of a biological structure is further disclosed.Type: ApplicationFiled: December 18, 2001Publication date: September 26, 2002Inventors: Zishan Haroon, Mark W. Dewhirst, Charles S. Greenberg, Michal Neeman
-
Patent number: 5858991Abstract: The method of the present invention provides a means of treating a patient having a wound, especially by minimizing scarring and accelerating wound healing, by administering CM101 or GBS toxin isolated from Group B .beta.-hemolytic streptococcus bacteria. The method of the present invention also includes administration of CM101 or GBS toxin to surgery patients having tumors in order to facilitate wound healing and minimize the likelihood of tumor progression.Type: GrantFiled: January 29, 1997Date of Patent: January 12, 1999Assignees: Vanderbilt University, Yeda Research & Development Co., Ltd.Inventors: Carl G. Hellerqvist, Michal Neeman, Barbara D. Wamil, Rinat Abramovitch